Entero Healthcare Solutions Limited has accepted the decision of Independent Director Rajesh Shashikant Dalal to not seek re-appointment for a second term. His current term concludes on August 24, 2026, marking the end of his tenure with the company. This transition impacts the composition of the board and its key committees effective the close of business hours on the specified date.

Rajesh Shashikant Dalal communicated his decision via email on July 13, 2026, stating he did not wish to be re-elected to the board upon the completion of his first term. Consequently, he will cease to be a Non-Executive Independent Director. The company has informed the stock exchanges regarding this change in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The departure involves the relinquishment of specific committee roles held by Dalal. He will step down as the Chairperson of the Nomination and Remuneration Committee and the Stakeholders Relationship Committee. Additionally, he will cease to be a member of the Audit Committee of the Board.

The following table summarizes the details of the cessation:

The disclosure was submitted to BSE Limited and the National Stock Exchange of India Limited by Sanu Kapoor, Vice President - Group General Counsel, Company Secretary & Compliance Officer. The information is also available on the company's official website.

Entero Healthcare Solutions allotted 1,475 equity shares to an eligible employee upon the exercise of options under the Entero Employee Stock Option Plan 2023. The shares, with a face value of Rs. 10 each, were issued at an exercise price of Rs. 804 per share. This issuance increases the company's total issued share capital to Rs. 43,52,30,720 and the total number of issued shares to 4,35,23,072. The shares rank pari-passu with existing equity shares and are not subject to any lock-in period restrictions.

The Board of Directors also approved the revised tenure for the re-appointment of Mr. Rajesh Shashikant Dalal and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors. The reappointments are for a second term of four consecutive years, commencing on August 25, 2026, and concluding on August 24, 2030. These decisions are subject to the approval of shareholders at the ensuing Annual General Meeting. The tenure of Mr. Sujesh Vasudevan, another Non-Executive Independent Director, remains unchanged.

ESOP Allotment Details

The company disclosed the specifics of the share allotment in compliance with SEBI regulations. The options were exercised based on the recommendations of the Nomination and Remuneration Committee.

Independent Director Reappointments

The board approved the reappointment of two independent directors to facilitate effective succession planning and ensure a smoother transition in the board's composition.

Mr. Rajesh Shashikant Dalal is a healthcare leader with over 35 years of experience, including roles as Managing Director of Johnson & Johnson India. Ms. Sandhya Gadkari Sharma brings over four decades of experience in banking and investment, having previously worked with Mahindra and Mahindra Limited and ICICI Bank Limited.